{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:08:32Z","timestamp":1784862512325,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>For patients with oligometastatic nodal recurrence after radical prostatectomy (RP), salvage radiotherapy is a valuable curative second-line treatment option. However, few clinical data on the impact of PSMA-PET\/CT-based salvage elective nodal radiotherapy (sENRT) is available. In order to contribute further clinical data on the outcome of patients treated with sENRT following RP, we analysed the rates of biochemical recurrence-free survival (BRFS) and distant metastasis-free survival (DMFS) as well as potential predictive markers for optimised patient selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of 76 patients treated with sENRT for nodal recurrence after RP was performed. Primary endpoints were BRFS and DMFS. Cox proportional hazards model was used to analyse potential predictive factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median follow-up was 32.6 months. PSMA-PET\/CT revealed 1, 2, or \u2265\u20093 positive lymph nodes in 63.2%, 30.2% and 6.6% of patients, respectively. 96% of the patients had pelvic-only lymph nodes involvement. One-, two- and three-year BRFS were 98.6%, 84.2%, and 71.9%, respectively. Notably, nodal status at the time of RP and biochemical-recurrence prior to sENRT, were associated with reduced BRFS. One-, two-, and three-year DMFS were 98.7%, 94.1%, and 94.1%, respectively, with paraaortic lymph nodes being the only factor indicating reduced DMFS. Concomitant androgen-deprivation therapy was applied in 85.5% of the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We present one of the largest studies on PSMA-PET-based sENRT for nodal recurrence after RP with promising results, highlighting the important role of sENRT. Regarding patient selection, initial lymph node status and prior radiation of the prostate were predictive of reduced BRFS, while involvement of paraaortic lymph nodes was identified as marker for reduced DMFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05950-5","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:59:47Z","timestamp":1758700787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PSMA-PET\/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1711-1604","authenticated-orcid":false,"given":"Samuel M.","family":"Vorbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Rittmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Nilica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"1","key":"5950_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005","journal-title":"Eur Urol"},{"issue":"3","key":"5950_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5950_CR3","unstructured":"Urology EAo (2025) EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025 ed: EAU Guidelines Office, Arnhem. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/;"},{"issue":"3","key":"5950_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172(3):910\u2013914. https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb","journal-title":"J Urol"},{"issue":"1","key":"5950_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","volume":"46","author":"F Ceci","year":"2019","unstructured":"Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S (2019) (68)Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 46(1):31\u201339. https:\/\/doi.org\/10.1007\/s00259-018-4189-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5950_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00197-4","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, L\u00f3pez Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Cou\u00f1ago F, Muto P, Zilli T (2025) Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(25)00197-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"5950_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed MiTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med 59(3):469\u2013478. https:\/\/doi.org\/10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"issue":"2","key":"5950_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","volume":"74","author":"CA Lawton","year":"2009","unstructured":"Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O\u2019Meara E, Rosenthal SA, Ritter M, Seider M (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383\u2013387. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5950_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","volume":"49","author":"P Rogowski","year":"2022","unstructured":"Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, Unterrainer M, Zacherl MJ, Ilhan H, Beyer L, Kretschmer A, Bartenstein P, Stief C, Belka C, Schmidt-Hegemann NS (2022) Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 49(4):1417\u20131428. https:\/\/doi.org\/10.1007\/s00259-021-05557-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5950_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5534\/wjmh.220066","volume":"41","author":"DB Lee","year":"2023","unstructured":"Lee DB, Kim JY, Song WH, Nam JK, Lee HJ, Kim TU, Park SW (2023) The impact of the percent of residual Prostate-Specific antigen on Metastasis-Free survival in patients with persistent Prostate-Specific antigen after radical prostatectomy. World J Mens Health 41(1):227\u2013235. https:\/\/doi.org\/10.5534\/wjmh.220066","journal-title":"World J Mens Health"},{"key":"5950_CR11","doi-asserted-by":"publisher","unstructured":"Kimura S, Urabe F, Sasaki H, Kimura T, Miki K, Egawa S (2021) Prognostic significance of Prostate-Specific antigen persistence after radical prostatectomy: A systematic review and Meta-Analysis. Cancers (Basel) 13(5). https:\/\/doi.org\/10.3390\/cancers13050948","DOI":"10.3390\/cancers13050948"},{"key":"5950_CR12","doi-asserted-by":"publisher","unstructured":"Tamihardja J, Zehner L, Hartrampf P, Lisowski D, Kneitz S, Cirsi S, Razinskas G, Flentje M, Polat B (2022) Salvage nodal radiotherapy as Metastasis-Directed therapy for oligorecurrent prostate cancer detected by positron emission tomography shows favorable outcome in Long-Term Follow-Up. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14153766","DOI":"10.3390\/cancers14153766"},{"issue":"12","key":"5950_CR13","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s12094-020-02364-0","volume":"22","author":"G Ingrosso","year":"2020","unstructured":"Ingrosso G, Mariucci C, Tenti MV, Bini V, Al\u00ec E, Saldi S, Palumbo I, Bellavita R, Aristei C (2020) Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer. Clin Transl Oncol 22(12):2236\u20132243. https:\/\/doi.org\/10.1007\/s12094-020-02364-0","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"5950_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bju.13510","volume":"119","author":"A Fodor","year":"2017","unstructured":"Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, Incerti E, Dell\u2019Oca I, Cozzarini C, Mangili P, Pasetti M, Calandrino R, Gianolli L, Di Muzio NG (2017) Toxicity and efficacy of salvage carbon 11-choline positron emission tomography\/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int 119(3):406\u2013413. https:\/\/doi.org\/10.1111\/bju.13510","journal-title":"BJU Int"},{"issue":"12","key":"5950_CR15","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1007\/s00259-024-06802-x","volume":"51","author":"C Trapp","year":"2024","unstructured":"Trapp C, Aebersold DM, Belka C, Casuscelli J, Emmett L, Eze C, Fanti S, Farolfi A, Fendler W, Grosu AL, Guckenberger M, Hruby G, Kirste S, Koerber SA, Kroeze S, Peeken JC, Rogowski P, Scharl S, Shelan M, Schmidt-Hegemann NS (2024) Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. Eur J Nucl Med Mol Imaging 51(12):3770\u20133781. https:\/\/doi.org\/10.1007\/s00259-024-06802-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5950_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1080\/0284186x.2021.1955970","volume":"60","author":"AM Werensteijn-Honingh","year":"2021","unstructured":"Werensteijn-Honingh AM, Wevers AFJ, Peters M, Kroon PS, Intven M, Eppinga WSC, J\u00fcrgenliemk-Schulz IM (2021) Progression-free survival in patients with (68)Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncol 60(10):1342\u20131351. https:\/\/doi.org\/10.1080\/0284186x.2021.1955970","journal-title":"Acta Oncol"},{"issue":"5","key":"5950_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10585-021-10122-x","volume":"38","author":"F Cuccia","year":"2021","unstructured":"Cuccia F, Mazzola R, Pastorello E, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Attin\u00e0 G, Vitale C, Ruggieri R, Alongi F (2021) SBRT for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity. Clin Exp Metastasis 38(5):475\u2013481. https:\/\/doi.org\/10.1007\/s10585-021-10122-x","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"5950_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00066-020-01605-z","volume":"196","author":"NS Schmidt-Hegemann","year":"2020","unstructured":"Schmidt-Hegemann NS, Buchner A, Eze C, Rogowski P, Schaefer C, Ilhan H, Li M, Fendler WP, Bartenstein P, Ganswindt U, Stief C, Belka C, Kretschmer A (2020) PSMA-positive nodal recurrence in prostate cancer: salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis. Strahlenther Onkol 196(7):637\u2013646. https:\/\/doi.org\/10.1007\/s00066-020-01605-z","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"5950_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eururo.2024.02.013","volume":"87","author":"L Vaugier","year":"2025","unstructured":"Vaugier L, Morvan C, Pasquier D, Buthaud X, Magn\u00e9 N, Beckendorf V, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Paul J, Blanc-Lapierre A, Supiot S (2025) Long-term outcomes and patterns of relapse following High-dose elective salvage radiotherapy and hormone therapy in oligorecurrent pelvic nodes in prostate cancer: OLIGOPELVIS (GETUG-P07). Eur Urol 87(1):73\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2024.02.013","journal-title":"Eur Urol"},{"key":"5950_CR20","doi-asserted-by":"publisher","unstructured":"Slevin F, Alexander S, Brown SR, Carter M, Choudhury A, Clipson A, Din O, Dive C, Gilbert A, Girvan S, Hingorani M, Jain S, Khoo V, Lilley J, Murray LJ, Naismith O, Noutch S, Oliveira P, Pagett CJH, Henry AM (2024) Pelvis or involved node treatment: eradicating recurrence in prostate cancer (POINTER-PC) - study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open 14(12):e095560. https:\/\/doi.org\/10.1136\/bmjopen-2024-095560","DOI":"10.1136\/bmjopen-2024-095560"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05950-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:03:17Z","timestamp":1767999797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05950-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5950"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05950-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no financial or non-financial conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee of the Medical University of Innsbruck (EC No. approval: 1092\/2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all the patients included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"571"}}